Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.5800 (-6.07%) ($7.5800 - $7.5800) on Wed. Mar. 24, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.57% (three month average) | RSI | 50 | Latest Price | $7.5800(-6.07%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -2.4% a day on average for past five trading days. | Weekly Trend | HTBX advances 0.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(40%) XBI(40%) ARKK(35%) IBB(35%) IPO(33%) | Factors Impacting HTBX price | HTBX will decline at least -4.285% in a week (0% probabilities). VIXM(-25%) VXX(-21%) IGOV(-16%) UUP(-14%) XLU(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.285% (StdDev 8.57%) | Hourly BBV | -1.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $8.27 | 5 Day Moving Average | $8.2(-7.56%) | 10 Day Moving Average | $8.47(-10.51%) | 20 Day Moving Average | $8.27(-8.34%) | To recent high | -39.6% | To recent low | 44.1% | Market Cap | $834m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |